Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations - Slideshow (NASDAQ:TARA) 2025-11-19
Protara TherapeuticsProtara Therapeutics(US:TARA) Seeking Alpha·2025-11-19 15:14

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]